Healthcare — Institutional Ownership & Hedge Fund Activity
Track hedge fund buying and selling activity in Healthcare stocks based on SEC 13F filings for Q2 2026.
Most Bought Healthcare Stocks
| # | Stock | Company | Funds Buying | Net $ Change |
|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | 102 | +$2.4B |
| 2 | ABBV | AbbVie Inc. | 91 | $-1.0B |
| 3 | JNJ | Johnson & Johnson | 80 | +$354.0M |
| 4 | MRK | Merck & Co., Inc. | 80 | +$281.5M |
| 5 | BMY | Bristol-Myers Squibb Company | 66 | $-408.1B |
| 6 | ABT | Abbott Laboratories | 61 | +$1.3T |
| 7 | PFE | Pfizer Inc. | 60 | $-245.5B |
| 8 | SYK | Stryker Corporation | 59 | $-2.3B |
| 9 | GILD | Gilead Sciences, Inc. | 54 | +$860.7M |
| 10 | MDT | Medtronic plc | 53 | $-201.4B |
| 11 | UNH | UnitedHealth Group Incorporated | 52 | +$2.2B |
| 12 | AMGN | Amgen Inc. | 48 | $-28.0M |
| 13 | ISRG | Intuitive Surgical, Inc. | 48 | $-4.2B |
| 14 | CI | Cigna Corporation | 45 | $-419.6M |
| 15 | TMO | Thermo Fisher Scientific Inc. | 45 | $-4.3B |
| 16 | CVS | CVS Health Corp. | 42 | $-1.8T |
| 17 | DHR | Danaher Corporation | 41 | $-7.6B |
| 18 | MCK | McKesson Corporation | 41 | $-35.2M |
| 19 | BDX | Becton, Dickinson and Company | 39 | +$190.6M |
| 20 | CAH | Cardinal Health, Inc. | 33 | +$260.5M |
Most Sold Healthcare Stocks
| # | Stock | Company | Funds Selling | Net $ Change |
|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | 127 | +$354.0M |
| 2 | MRK | Merck & Co., Inc. | 106 | +$281.5M |
| 3 | ABBV | AbbVie Inc. | 95 | $-1.0B |
| 4 | AMGN | Amgen Inc. | 86 | $-28.0M |
| 5 | PFE | Pfizer Inc. | 86 | $-245.5B |
| 6 | UNH | UnitedHealth Group Incorporated | 83 | +$2.2B |
| 7 | ABT | Abbott Laboratories | 82 | +$1.3T |
| 8 | LLY | Eli Lilly and Company | 81 | +$2.4B |
| 9 | TMO | Thermo Fisher Scientific Inc. | 78 | $-4.3B |
| 10 | DHR | Danaher Corporation | 65 | $-7.6B |
| 11 | MDT | Medtronic plc | 61 | $-201.4B |
| 12 | SYK | Stryker Corporation | 57 | $-2.3B |
| 13 | BMY | Bristol-Myers Squibb Company | 56 | $-408.1B |
| 14 | ISRG | Intuitive Surgical, Inc. | 56 | $-4.2B |
| 15 | CVS | CVS Health Corp. | 52 | $-1.8T |
| 16 | GILD | Gilead Sciences, Inc. | 52 | +$860.7M |
| 17 | VRTX | Vertex Pharmaceuticals Incorporated | 47 | +$144.7M |
| 18 | ZTS | Zoetis Inc. | 47 | +$789.7B |
| 19 | MCK | McKesson Corporation | 46 | $-35.2M |
| 20 | BSX | Boston Scientific Corporation | 43 | $-1.2T |
Explore More
Data sourced from SEC 13F filings for Q2 2026. Filings are delayed up to 45 days after quarter end.